Table 4 The top 10 co-cited references
Title | Citation | Authorsa | Pub. year | Journals |
|---|---|---|---|---|
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial | 47 | Hanauer, Stephen | 2002 | Lancet |
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study | 40 | Beaugerie, Laurent | 2009 | Lancet |
Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease | 38 | Colombel, Jean-Frederic | 2010 | The New England Journal of Medicine |
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis | 33 | Rutgeerts, Paul | 2005 | The New England Journal of Medicine |
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease | 31 | Rahier, Jean-Francois | 2014 | Journal of Crohn’s and Colitis |
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial | 29 | Colombel, Jean-Frederic | 2007 | Gastroenterology |
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease | 29 | Toruner, Murat | 2008 | Gastroenterology |
Epstein–Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine | 27 | Dayharsh, Gerald | 2002 | Gastroenterology |
Infliximab Maintenance Therapy for Fistulizing Crohn’s Disease | 26 | Sands, Bruce | 2004 | The New England Journal of Medicine |
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α | 24 | Targan, Stephan | 1997 | The New England Journal of Medicine |